Skip to main content

Greg Calaman, Rob Friel, Gregory Summe

Premium
Definiens this week announced that Greg Calaman has been named vice president of its operations in North America. Calaman has been a member of Definiens’ management team since April 2006. 
 
Calaman was previously part of the worldwide IT leadership team at Pfizer. He serves on the Advisory Council of the Krall Center for Executive Education at Drexel University and on the Board of Advisors to the Trestle Group Foundation of London.
 

 
PerkinElmer this week announced that Rob Friel, president of the company’s Life and Analytical Sciences business, will succeed Gregory Summe as CEO in February.
 
Initially, Friel will become president and chief operating officer of PerkinElmer on Aug. 1, and the firm expects him to be elected CEO six months later. At that time, Summe will become executive chairman of the board, a title he will retain through the annual shareholders meeting in April 2009, PerkinElmer said.
 
Friel joined the company in 1999 as chief financial officer and was appointed vice chairman, director, and president of the LAS business in 2006. In his new role, Friel will be responsible for both LAS and the Optoelectronics business.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.